Geneva, May 28 -- International Clinical Trials Registry received information related to the study (NCT06964737) titled 'Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas' on May 1.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Ohio State University Comprehensive Cancer Center
Condition:
Recurrent Malignant Glioma
Recurrent WHO Grade 3 Glioma
Recurrent WHO Grade 4 Glioma
WHO Grade 2 Glioma
WHO Grade 3 Glioma
WHO Grade 4 Glioma
Intervention:
Biological: Anti-GARP Chimeric Antigen Receptor-T Cells
Procedure: Biospecimen Collection
Procedure: Chest Ra...